Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Cardiol. Dec 26, 2020; 12(12): 615-625
Published online Dec 26, 2020. doi: 10.4330/wjc.v12.i12.615
Table 1 Baseline demographics and clinical characteristics
Characteristicsn = 77
Age (mean ± SD), yr55 ± 11.8
Men, n (%)59 (76.6)
Medical history, n (%)
Hypertension37 (48.1)
Diabetes15 (19.48)
Smoking24 (31.2)
Consumption of alcohol9 (11.7)
Stroke2 (2.6)
Previous coronary intervention4 (5.2)
Previous myocardial infarction34 (44.2)
Cardiac status, n (%)
Stable angina30 (39)
Unstable angina13 (16.9)
STEMI26 (33.8)
NSTEMI8 (10.4)
Coronary angiogram finding, n (%)
Single-vessel disease61 (79.2)
Double-vessel disease16 (20.8)
Triple-vessel disease0 (0.0)
Heart rate (mean ± SD), bpm81.26 ± 12.08
Systolic blood pressure (mean ± SD), mmHg134.91 ± 27.51
Diastolic blood pressure (mean ± SD), mmHg83.19 ± 13.57
Serum creatinine (mean ± SD), mg/dL1.13 ± 0.23
LVEF (mean ± SD), %46.38 ± 8.19
Table 2 Procedural and lesion characteristics
Characteristicsn = 77
Access site approach, n (%)
Femoral20 (26)
Radial57 (74)
Total number of lesions102
Total number of lesions treated with EverProTM98
Lesions per patient1.32
Stents per patient1.27
Lesion location, n (%)
Right carotid artery29 (29.6)
Left anterior descending artery48 (49)
Left circumflex artery12 (12.2)
Obtuse marginal artery9 (9.2)
Stenosis type, n (%)
De novo95 (96.9)
In-stent3 (3.1)
Thrombus load, n (%)
None76 (77.6)
Mild10 (10.2)
Moderate5 (5.1)
Severe7 (7.1)
ACC/AHA lesion type, n (%)
A5 (5.1)
B130 (30.6)
B238 (38.8)
C25 (25.5)
Percent stenosis (mean ± SD)88.39 ± 9.30
Stent length (mean ± SD), mm18.20 ± 4.34
Stent diameter (mean ± SD), mm2.89 ± 0.36
TIMI flow post-procedure, n (%)
TIMI 398 (100)
Discharge medications, n (%)
Aspirin77 (100)
Clopidogrel44 (57.1)
Ticlopidine2 (2.6)
Prasugrel3 (3.9)
Ticagrelor27 (35.1)